Country-based report: The safety of omalizumab treatment in pregnant patients with asthma

Simple item page
dc.contributor.authorGemicioğlu B.
dc.contributor.authorYalçin A.D.
dc.contributor.authorHavlucu Y.
dc.contributor.authorKarakaya G.
dc.contributor.authorÖzdemir L.
dc.contributor.authorKeren M.
dc.contributor.authorBavbek S.
dc.contributor.authorEdiger D.
dc.contributor.authorOğuzülgen İ.K.
dc.contributor.authorÖzşeker Z.F.
dc.contributor.authorYorgancioğlu A.
dc.date.accessioned2025-04-10T11:05:56Z
dc.date.available2025-04-10T11:05:56Z
dc.date.issued2021
dc.description.abstractBackground/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants. © TÜBİTAK.
dc.identifier.DOI-ID10.3906/SAG-2101-341
dc.identifier.urihttp://hdl.handle.net/20.500.14701/46369
dc.publisherTurkiye Klinikleri
dc.titleCountry-based report: The safety of omalizumab treatment in pregnant patients with asthma
dc.typeArticle

Files

Collections

Scopus Koleksiyonu